pab research summary #2

1.

From the 27MAR14 ASX Announcement "Final Data Confirms Successful Phase I/IIa Clinical Trial for PAT-SM6", paragraph 6:

"These data compare favorably with another antibody (Elotuzumab)..."


1.1

What happened with Elotuzumab ($710M):

"Bristol-Myers Squibb is paying $30 million upfront in a licensing deal....And it will pay up to $680 million more if the Phase I cancer therapy hits all of its development and sales milestones."

http://www.fiercebiotech.com/story/bms-inks-710m-development-deal-pdl/2008-08-20


1.3

PAB's current market cap ~$30M.